Monoclonal antibodies, such as CD38 and signaling lymphocytic activation molecule family member 7 (SLAMF7), targeting cell surface markers, and have significant efficacy in MM patients [27,28,29]. Here, SLAMF7 is linked to Miyoshi myopathy.